Cogent Biosciences (COGT) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Piper Sandler | Maintained | Overweight | $55.00 from $52.00 | Aug 17, 2026 |
| Guggenheim | Maintained | Buy | $52.00 from $45.00 | Aug 12, 2026 |
| Wedbush | Maintained | Outperform | $55.00 | May 29, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $55.00 from $52.00 | May 6, 2026 |
| Wedbush | Maintained | Outperform | $55.00 | Mar 17, 2026 |
| Jefferies | Initiated Coverage | Buy | $55.00 | Mar 16, 2026 |
| Piper Sandler | Maintained | Overweight | $52.00 from $39.00 | Feb 18, 2026 |
| Wedbush | Maintained | Outperform | $55.00 | Jan 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $52.00 from $50.00 | Jan 6, 2026 |
| JP Morgan | Maintained | Overweight | $67.00 from $65.00 | Dec 19, 2025 |
| Needham | Maintained | Hold | — | Dec 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $50.00 from $21.00 | Nov 13, 2025 |
| Baird | Maintained | Neutral | $34.00 from $14.00 | Nov 11, 2025 |
| Leerink Partners | Maintained | Outperform | $50.00 from $18.00 | Nov 10, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Nov 4, 2025 |
| JP Morgan | Maintained | Overweight | $44.00 from $30.00 | Oct 21, 2025 |
| Stifel | Initiated Coverage | Hold | $16.00 | Oct 16, 2025 |
| Raymond James | Initiated Coverage | Strong Buy | $30.00 | Sep 3, 2025 |
| Guggenheim | Maintained | Buy | $20.00 from $17.00 | Aug 25, 2025 |
| JP Morgan | Maintained | Overweight | $30.00 from $29.00 | Aug 7, 2025 |
Frequently asked questions
Is COGT a buy, sell, or hold?
Analysts covering Cogent Biosciences currently average a Buy rating: 11 buy, 1 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on COGT?
On Aug 17, 2026, Piper Sandler maintained Cogent Biosciences at Overweight with a price target of $55.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.